Company profile

Molecular Partners AG

Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches.

Source: startup.ch

Highlights

Innosuisse Certificate

More news about Molecular Partners AG

30.05.2023 14:21

Positive results for Swiss biotechs’ clinical studies

Success

16.01.2023 10:40

Listed Swiss Biotechs at full throttle

Success

10.01.2022 08:20

Molecular Partners’ COVID-19 drug demonstrates efficacy

Success

16.11.2021 13:39

Molecular Partners' Covid 19 drug falters in Phase 3 trials

Setback

21.06.2021 09:56

Encouraging progress of COVID-19 solutions from Switzerland

Background

Success

25.11.2020 16:56

Development milestones for startups with Corona solutions

Success

28.10.2020 10:47

Novartis joins Molecular Partners as investor and collaboration partner

Financing

Success

11.08.2020 08:20

Swiss Government to buy anti-COVID-19 drugs from Molecular Partners

Support

07.07.2020 09:48

Molecular Partners raises CHF80 million via private placement

Financing

26.06.2020 09:18

Major setback for Molecular Partners

Setback

19.07.2018 15:04

Positive phase 3 results for Molecular Partner’s most advanced molecule

Success

03.01.2018 11:50

Two biotech startups receive milestone payments

Financing

10.12.2015 09:13

Molecular Partners among the best newcomers at European stock exchanges

Award

09.11.2015 10:39

Molecular Partner’s DARPins may help reshape anticancer treatment

Success

07.10.2015 08:50

Molecular Partners honoured for its pioneering technology

Award

24.07.2015 11:55

Discovery alliance with Roche discontinued

Setback

22.07.2015 08:25

Allergan reinforces commitment to Molecular Partners

Success

07.07.2015 08:53

Molecular Partners receives USD 15 million milestone payment

Success

09.12.2014 08:27

Milestone payment from Janssen for Molecular Partners

03.11.2014 09:20

Molecular Partners: IPO on 5 November

21.10.2014 18:07

Molecular Partners puts IPO on hold

08.10.2014 15:55

Molecular Partners: First trading day expected for 22 October 2014

23.09.2014 08:30

Molecular Partners launches IPO on SIX Swiss Exchange

22.09.2014 07:21

Molecular Partners one of the most promising biotech companies worldwide

Award

03.07.2014 10:46

Molecular Partners: Phase III development of a DARPin on the horizon

04.12.2013 09:47

Molecular Partners enters into another billion dollar alliance

17.01.2013 13:39

Molecular Partners publishes encouraging results of a clinical study

21.08.2012 10:59

Molecular Partners signs Billion Dollar Contract with Allergan

08.12.2011 14:51

Molecular Partners enters into a Strategic Collaboration with Janssen Biotech

28.04.2011 21:15

Molecular Partners reports positive results from its first clinical studies MP0112 is safe and effec

Founded
2004

Homepage

Principal

Swiss Venture Capital Report

The new Swiss Venture Capital Report provides a review of the whole of 2023. In addition to investments, the report will once again include the results of a survey of Swiss investors, an overview of venture capital fundraising and a list of exits. You can download the Report in our asset section.